IGF::OT::IGF OPERATION OF GOVERNMENT-OWNED CONTRACTOR-OPERATED (GOCO) R&D FACILITIES

引起疾病的新出现/重新出现和相关呼吸道病毒，如SARS、流感和MERS-CoV，由于其显著的发病率和快速地理传播的潜力，特别值得关注。 这一目标支持更好地了解疾病和治疗方案的总体目标，并改善患有新发和再发及相关呼吸道病毒的患者的医疗结果。国家过敏和传染病研究所（NIAID）/临床研究部（DCR）预计支持将表征流感自然史，流感样疾病，和其他呼吸道疾病，并涵盖不同严重程度的疾病，使用模型和方法，可以迅速调整。 NIAID预计，为了支持研究的开展，Leidos Biomedical将： 1. 提供科学、临床和技术领导 2. 采购完成方案所需的所有材料和用品 3. 负责以下领域的计划/项目管理： a. 临床研究管理 B. 数据管理 C. 生物统计分析和报告。

Emerging/re-emerging and related respiratory viruses causing disease, such as SARS, influenza, and MERS-CoV, are of particular concern given their significant morbidity and potential for rapid geographic spread. This objective supports the overall goal to better understand the diseases and therapeutic options and to improve medical outcomes for patients afflicted with the emerging and re-emerging and related respiratory viruses.The National Institute of Allergy and Infectious Diseases (NIAID) / Division of Clinical Research (DCR) anticipates supporting studies that will characterize the natural history of influenza, influenza-like-illness, and other respiratory diseases across several different geographic areas and resource settings, and encompass different severities of disease using models and methodologies that can be adapted rapidly. NIAID anticipates that in order to support conduct of the studies, Leidos Biomedical will: 1. Provide scientific, clinical, and technical leadership 2. Procure all materials and supplies necessary to complete the protocols 3. Be responsible for program/project management in the areas of: a. Clinical research management b. Data management c. Biostatistical analysis and reporting.